In December 2023, Sydney-based tech entrepreneur Paul Conyngham received devastating news: his beloved border collie, Rosie, had been diagnosed with cancer. Despite aggressive chemotherapy and surgery, the tumors persisted, and Rosie’s health rapidly declined, leaving Conyngham desperate for an alternative solution. Leveraging his background in artificial intelligence and a willingness to push the boundaries of conventional medicine, he turned to AI tools—including OpenAI’s ChatGPT and Google DeepMind’s AlphaFold—to design a first-of-its-kind personalized mRNA cancer vaccine for Rosie. Just months later, the experimental treatment has shrunk most of her tumors, restored her energy, and even allowed her to chase rabbits again, offering a glimmer of hope not only for veterinary oncology but also for the future of human cancer treatment.
- A Sydney tech entrepreneur used AI tools like ChatGPT and AlphaFold to design a bespoke mRNA cancer vaccine for his dog Rosie after conventional treatments failed.
- The vaccine, developed in collaboration with University of New South Wales scientists, marks the first personalized cancer immunotherapy for a canine patient.
- Rosie’s tumors have dramatically shrunk since receiving the vaccine, and her energy levels have improved, though not all tumors have responded.
- Experts say Rosie’s case demonstrates the potential of AI and mRNA technology to democratize personalized medicine in both veterinary and human healthcare.
The Making of a World-First: How AI and mRNA Converged to Fight Canine Cancer
Paul Conyngham’s journey to create Rosie’s personalized cancer vaccine began not in a lab, but in a chatbot interface. Faced with Rosie’s grim prognosis after failed chemotherapy, Conyngham—a cofounder of Core Intelligence Technologies and former director of the Data Science and AI Association of Australia—turned to OpenAI’s ChatGPT for guidance. The AI assistant suggested immunotherapy as a potential avenue, pointing Conyngham toward cutting-edge research in personalized cancer treatments. This led him to the University of New South Wales (UNSW) Ramaciotti Center for Genomics, where he connected with researchers willing to explore the unconventional approach.
From AI Prompts to AlphaFold: Mapping Rosie’s Genetic Weaknesses
Conyngham’s lack of medical training was no barrier to his mission. With ChatGPT’s guidance, he crafted a step-by-step plan to identify potential cancer targets in Rosie’s DNA. To pinpoint the specific genetic mutations driving her tumors, he employed AlphaFold, DeepMind’s AI system designed to predict protein structures. By analyzing Rosie’s genomic data, AlphaFold helped identify mutated proteins that could serve as targets for an immunotherapy treatment. ‘I went to ChatGPT and came up with a plan on how to do this,’ Conyngham told *The Australian*. The AI-driven approach allowed him to bypass traditional medical gatekeepers and directly access the tools needed to explore experimental treatments.
However, the path wasn’t smooth. After identifying a promising immunotherapy candidate, Conyngham reached out to pharmaceutical companies for access to the drug—only to be met with refusal. Undeterred, he pressed forward, funding Rosie’s genomic sequencing through UNSW and continuing his research. This persistence would soon pay off when he crossed paths with a leading figure in nanomedicine.
Pall Thordarson and the Birth of a Bespoke mRNA Vaccine
Enter Pall Thordarson, director of UNSW’s RNA Institute and a pioneer in nanomedicine. Thordarson, whose work focuses on RNA-based therapies, saw potential in Conyngham’s data and the AI-generated insights. Within weeks, his team developed a custom mRNA vaccine tailored to Rosie’s specific cancer mutations. ‘This is the first time a personalized cancer vaccine has been designed for a dog,’ Thordarson told *The Australian*. ‘This is still at the frontier of where cancer immunotherapeutics are—and ultimately, we’re going to use this for helping humans. What Rosie is teaching us is that personalized medicine can be very effective, and done in a time-sensitive manner, with mRNA technology.’
Rosie’s Remarkable Recovery: Tumors Shrink, Energy Returns, But Challenges Remain
Rosie received her first injection of the experimental vaccine in December 2023, followed by a booster in February 2024. The results have been nothing short of remarkable. ‘Most of her tumors have already shrunk dramatically,’ Thordarson noted. Conyngham described a stark improvement in Rosie’s quality of life: ‘In December she had low energy because the tumors were creating a huge burden for her. Six weeks post-treatment, I was at the dog park when she spotted a rabbit and jumped the fence to chase it.’ While not all tumors have responded to the vaccine, the treatment has bought Rosie precious time and significantly enhanced her well-being.
‘I’m under no illusion that this is a cure, but I do believe this treatment has bought Rosie significantly more time and quality of life.’ — Paul Conyngham, Sydney tech entrepreneur and Rosie’s owner
A Glimpse into the Future: AI, mRNA, and the Democratization of Personalized Medicine
Rosie’s case is more than a heartwarming story of a dog beating the odds—it’s a proof-of-concept for how AI and mRNA technology could revolutionize both veterinary and human medicine. Thordarson emphasized this potential in a recent post on X (formerly Twitter), writing that Rosie’s journey demonstrates how technology can ‘democratize’ the process of designing cancer vaccines. By enabling non-experts to harness AI tools and genomic data, such approaches could accelerate the development of personalized treatments, making them more accessible and affordable.
The implications extend beyond canine health. mRNA technology, which gained global recognition during the COVID-19 pandemic, has already shown promise in human cancer vaccines. Companies like BioNTech and Moderna are actively researching personalized mRNA cancer immunotherapies, with early clinical trials underway. Rosie’s case suggests that the same principles—tailoring treatments to a patient’s unique genetic profile—could be applied to humans, potentially transforming oncology from a one-size-fits-all approach to a precision medicine model.
Reactions from the Tech and Medical Communities: Hope, Skepticism, and a Glimpse of the ‘Weird Future’
Rosie’s story has captivated both the tech and medical communities, sparking discussions about the accelerating pace of innovation at the intersection of AI and healthcare. Matt Shumer, cofounder and CEO of OthersideAI, took to X to highlight Rosie’s case, tweeting, ‘This is what I mean when I say the world is going to get very weird, very soon. Expect more stories like this, each sounding increasingly more insane.’ His remarks underscore the growing sense of awe—and at times unease—surrounding AI’s role in fields traditionally dominated by human expertise.
Medical professionals have also weighed in, with many praising Rosie’s case as a groundbreaking example of translational research. Dr. Alice Villalobos, a veterinary oncologist unaffiliated with the project, noted that while personalized vaccines for pets are not entirely new, the use of AI to design them is unprecedented. ‘This is a testament to how far we’ve come in integrating technology into medicine,’ she said. ‘If this approach can be validated in larger studies, it could open doors for similar treatments in humans.’
The Road Ahead: Challenges, Ethical Questions, and the Promise of Precision Oncology
Despite the promising results, Rosie’s case also highlights the challenges and ethical dilemmas surrounding AI-driven medical innovations. One major hurdle is the lack of standardized regulations for AI-generated medical treatments, particularly in veterinary medicine. While Conyngham and Thordarson’s collaboration was driven by desperation, the absence of rigorous clinical trials raises questions about safety, efficacy, and reproducibility. Additionally, the high cost of genomic sequencing and personalized therapies could limit accessibility, exacerbating existing disparities in healthcare.
Regulatory and Ethical Considerations
Veterinary oncologists and bioethicists are calling for clearer guidelines to govern the use of AI in treatment design. Dr. Lisa Moses, a veterinarian and bioethicist at Harvard Medical School, emphasized the need for transparency in how AI tools are used to make medical decisions. ‘We have to ensure that these technologies are validated and that their limitations are clearly communicated,’ she said. ‘AI can be a powerful tool, but it’s not infallible.’
Scaling Personalized Medicine: Can It Work Beyond Rosie?
Another critical question is whether Rosie’s treatment can be replicated on a larger scale. The bespoke nature of mRNA vaccines means each one is tailored to a specific patient’s genetic profile, a process that is both time-consuming and expensive. Thordarson’s team at UNSW is now exploring ways to streamline vaccine production, but significant hurdles remain. ‘This is still early-stage research,’ Thordarson cautioned. ‘We need more data to understand how broadly applicable this approach is.’
A Broader Shift in Oncology: From Pets to People
Rosie’s story is part of a larger trend in oncology toward precision medicine, where treatments are customized based on a patient’s genetic and molecular characteristics. The success of mRNA vaccines in COVID-19 has accelerated research into their potential for cancer, with companies like BioNTech (which partnered with Pfizer for the COVID-19 vaccine) now leading the charge in human trials. If Rosie’s case is any indication, the future of cancer treatment may lie in harnessing AI to rapidly identify targets and deploy personalized therapies at scale.
What This Means for Pet Owners and the Veterinary Industry
For pet owners, Rosie’s story offers a glimmer of hope in the face of devastating diagnoses. While personalized cancer vaccines are not yet widely available, the success of Rosie’s treatment suggests that such options may become more feasible in the coming years. Veterinary schools and research institutions are increasingly exploring AI and genomic tools, signaling a potential shift in how pets are treated for cancer.
However, the high cost of these treatments—Conyngham paid for Rosie’s genomic sequencing out of pocket—remains a significant barrier. As demand grows, veterinary professionals are calling for insurance coverage and subsidies to make personalized therapies more accessible. ‘This technology has the potential to change the landscape of veterinary oncology,’ said Dr. Jessica Vogelsang, a veterinarian and writer. ‘But we need to ensure it doesn’t become a luxury only the wealthy can afford.’
The Human Connection: Why Rosie’s Story Resonates Beyond the Veterinary World
Beyond its veterinary significance, Rosie’s case serves as a powerful reminder of the human spirit’s capacity to innovate in the face of adversity. Conyngham’s journey—from using ChatGPT to designing a bespoke vaccine—embodies the DIY ethos of the tech world, where boundaries between disciplines are increasingly blurred. His story also highlights the importance of interdisciplinary collaboration, as a tech entrepreneur and a nanomedicine expert joined forces to tackle a problem neither could solve alone.
Key Takeaways: What Rosie’s Breakthrough Means for the Future
- AI tools like ChatGPT and AlphaFold enabled a non-expert to design a personalized mRNA cancer vaccine for a dog, demonstrating the democratizing potential of technology in medicine.
- Rosie’s tumors have shrunk dramatically after receiving the experimental vaccine, though not all have responded, underscoring both the promise and limitations of personalized oncology.
- The case highlights the convergence of AI, mRNA technology, and genomics, offering a potential model for future cancer treatments in both pets and humans.
- Regulatory and ethical challenges remain, including the need for standardized guidelines and affordable access to personalized therapies.
- Experts caution that while Rosie’s story is groundbreaking, it represents early-stage research that requires further validation before widespread adoption.
Frequently Asked Questions About Rosie’s AI-Powered Cancer Vaccine
Frequently Asked Questions
- Can AI design personalized cancer treatments for humans as it did for Rosie?
- AI is already being used to accelerate cancer research in humans, including identifying genetic mutations and predicting protein structures. Companies like BioNTech and Moderna are testing personalized mRNA cancer vaccines in clinical trials, suggesting that Rosie’s approach could one day apply to human patients.
- How much did it cost to develop Rosie’s personalized vaccine?
- While exact costs are not publicly disclosed, Conyngham reportedly paid for Rosie’s genomic sequencing out of pocket. Personalized cancer vaccines are typically expensive due to the advanced technology and labor involved, though future innovations may reduce these costs.
- Is this the first time a personalized cancer vaccine has been used in veterinary medicine?
- While personalized cancer treatments for pets exist, Rosie’s case is believed to be the first to employ an AI-designed mRNA vaccine tailored to a specific dog’s genetic profile, marking a significant milestone in veterinary oncology.
